Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Green Hornet stung again

This article was originally published in The Tan Sheet

Executive Summary

FDA expands upon February consumer alert on the street drug alternative Green Hornet to include "all other products by Cytotech Solutions," agency announces April 9. In analyses of additional Cytotech products, FDA identified presence of diphendydramine HCl, dextromethorphan, ephedrine and the controlled substances GBL and GHB. The products include Snuffadelic, Liquid Speed and Trip2Night. "Although the company is no longer producing these products, they remain under investigation," FDA says, adding it "is issuing this warning because consumers may still have these products in their possession," agency notes. FDA issued the Green Hornet alert after four teenagers were hospitalized with excessive heart rates and high blood pressure after taking the liquid manufactured by Cytotech and marketed by Kekio (1"The Tan Sheet" March 1, 2004, p. 15)...
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS096718

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel